Coya Therapeutics Stock (NASDAQ:COYA)


ForecastRevenueFinancialsChart

Previous Close

$5.66

52W Range

$4.75 - $10.69

50D Avg

$7.07

200D Avg

$7.37

Market Cap

$93.73M

Avg Vol (3M)

$89.50K

Beta

0.79

Div Yield

-

COYA Company Profile


Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an allogeneic Treg exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company was incorporated in 2020 and is headquartered in Houston, Texas.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

8

IPO Date

Dec 29, 2022

Website

COYA Performance


COYA Financial Summary


Dec 23Dec 22Dec 21
Revenue$6.00M--
Operating Income$-7.36M$-9.81M$-4.87M
Net Income$-7.99M$-14.68M$-4.87M
EBITDA$-7.33M$-9.78M$-4.88M
Basic EPS$-0.79$-5.67$-0.74
Diluted EPS$-0.79$-5.67$-0.74

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
CUECue Biopharma, Inc.
CNTACentessa Pharmaceuticals plc
TCRXTScan Therapeutics, Inc.
DAWNDay One Biopharmaceuticals, Inc.
HLVXHilleVax, Inc.
STROSutro Biopharma, Inc.
FENCFennec Pharmaceuticals Inc.
GANXGain Therapeutics, Inc.
TERNTerns Pharmaceuticals, Inc.
DRMADermata Therapeutics, Inc.
INZYInozyme Pharma, Inc.
LTRNLantern Pharma Inc.
ABOSAcumen Pharmaceuticals, Inc.
TFFPTFF Pharmaceuticals, Inc.
INABIN8bio, Inc.
CGTXCognition Therapeutics, Inc.
OPTOpthea Limited